« Back

GTx, Inc. Announces Appointment of Director of Marketing and Sales to Management Team

Feb 11, 2004 at 12:00 AM EST
Contact:
GTx, Inc.
Carney Duntsch
Investor and Media Relations
901-523-9700 ext. 170
cduntsch@gtxinc.com
 

Burns McClellan, Inc.
Jonathan M. Nugent (investors)
Kathy L. Jones-Nugent, Ph.D. (media)
212-213-0006







GTx, Inc. Announces Appointment of Director of Marketing and Sales to Management Team

MEMPHIS, TENNESSEE, Feburary 11, 2004 å GTx, Inc. (Nasdaq: GTXI), a biopharmaceutical company dedicated to the development and commercialization of therapeutic products related to men's health, today announced the appointment of Greg Deener as Director, Marketing and Sales. In this position, Mr. Deener will be responsible for the strategic design and implementation of marketing and sales strategies for the Company. Mr. Deener comes to GTx from GlaxoSmithKline (GSK), where most recently he held the position of Director, Avodart Marketing. Prior to his time at GSK, Mr. Deener was a Brand Manager at Procter & Gamble Company.

"We are excited to welcome Mr. Deener to our management team," stated Mitchell Steiner, M.D., Vice Chairman and CEO of GTx. "Sales and Marketing are an important area of focus as we advance the Company's product candidates through the development and approval phases. We are pleased to have such a qualified individual handling this aspect of the business."

Mr. Deener brings over 20 years experience in the design and execution of sales and marketing for several successful products.

About GTx
GTx is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics primarily related to the treatment of serious men's health conditions. GTx's drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens. GTx currently has two product candidates that are in human clinical trials. The company is developing Acapodene™, its most advanced product candidate, through clinical trials for two separate indications: (1) a Phase IIb clinical trial for the reduction in the incidence of prostate cancer in men with precancerous prostate lesions and (2) the pivotal Phase III clinical trial for the treatment of serious side effects of advanced prostate cancer therapy. GTx is initially developing its second product candidate, Andarine, for the treatment of muscle wasting weight loss, or cachexia, that occurs from various types of cancer.